Medtronic Bets On Blockbuster Hypertension Market With Ardian Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's $800-million-plus bet on still-early-stage catheter technology for treating hypertension is a risk worth taking, company watchers suggest, considering many of the device giant's core offerings are in mature markets with paltry growth prospects.
You may also be interested in...
Cardio Catch-Up: Medtronic Still Has Work To Do On RDN After FDA Advisory Panel
FDA’s circulatory system advisory panel narrowly voted against Medtronic’s Symplicity Spyral, because one of the pivotal trials of the radiofrequency renal denervation system missed its primary endpoint and the patient population evaluated in the trial does not match the requested indication.
Symplicity Makes Life Difficult For Renal Denervation Programs
A big slice of the device industry, from large-cap firms to venture capitalists, is trying to understand the new reality in the wake of Medtronic’s announcement that its Symplicity hypertension trial missed its endpoint
Boston Scientific Enters Renal Denervation Market Via Vessix Acquisition
Deal gives Boston Scientific access to the V2 radiofrequency energy-based renal denervation catheter system for drug-resistant hypertension.